The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas-Reference-Cited by-同舟云学术

The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas

Published:2020-01-22 Issue:527 Volume:12 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Gargini Ricardo¹²^ORCID,Segura-Collar Berta²^ORCID,Herránz Beatriz²³^ORCID,García-Escudero Vega¹⁴^ORCID,Romero-Bravo Andrés²^ORCID,Núñez Felipe J.⁵^ORCID,García-Pérez Daniel⁶^ORCID,Gutiérrez-Guamán Jacqueline⁷^ORCID,Ayuso-Sacido Angel⁸⁹¹⁰,Seoane Joan¹¹¹²¹³,Pérez-Núñez Angel⁶^ORCID,Sepúlveda-Sánchez Juan M.⁷,Hernández-Laín Aurelio⁷^ORCID,Castro María G.⁵^ORCID,García-Escudero Ramón⁷¹²¹⁴^ORCID,Ávila Jesús¹¹⁵^ORCID,Sánchez-Gómez Pilar²^ORCID

Affiliation:

1. Centro de Biología Molecular “Severo Ochoa” (CSIC-UAM), Madrid 28049, Spain.

2. Neurooncology Unit, Instituto de Salud Carlos III-UFIEC, Madrid 28220, Spain.

3. Facultad de Medicina de la Universidad Francisco de Vitoria, Madrid 28223, Spain.

4. Dto. de Anatomía, Histología y Neurociencia, Facultad de Medicina de la Universidad Autónoma, Madrid 28029, Spain.

5. Department of Neurosurgery/Department of Cell & Developmental Biology, University of Michigan School of Medicine, Ann Arbor, MI 48109, USA.

6. Dto. Neurocirugía, Hospital 12 de Octubre, Univ. Complutense, Madrid 28041, Spain.

7. Instituto de Investigaciones Biomédicas I+12, Hosp. 12 de Octubre, Madrid 28041, Spain.

8. Fundación de Investigación HM Hospitales, HM Hospitales, Madrid 28015, Spain.

9. Facultad de Medicina (IMMA), Universidad San Pablo-CEU, Madrid 28925, Spain.

10. IMDEA Nanoscience, Madrid 28049, Spain.

11. Vall d'Hebron Institute of Oncology (VHIO), Barcelona 08035, Spain.

12. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), ISCIII, Madrid 28029, Spain.

13. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona 08010, Spain.

14. Unidad de Oncología Molecular, CIEMAT, Madrid 28040, Spain.

15. Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), ISCIII, Madrid 28029, Spain.

Abstract

TAU is expressed in the less aggressive gliomas where it impairs the mesenchymal transdifferentiation of tumor cells and normalizes the vasculature.

Funder

NIH Office of the Director

Fundación Científica Asociación Española Contra el Cáncer

Ministerio de Economía, Industria y Competitividad, Gobierno de España

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference63 articles.

1. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

2. IDH1andIDH2Mutations in Gliomas

3. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

4. IDH mutation impairs histone demethylation and results in a block to cell differentiation

5. Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization and expression of the microtubule associated protein tau gene isoforms and their impact on clinical outcomes in glioma patients;Computational and Structural Biotechnology Reports;2024-12

2. GBM immunotherapy: Exploring molecular and clinical frontiers;Life Sciences;2024-11

3. ALKBH5-mediated N6-methyladenosine modification of HO-1 mRNA regulates ferroptosis in cobalt-induced neurodegenerative damage;Environment International;2024-08

4. Insights into Dysregulated Neurological Biomarkers in Cancer;Cancers;2024-07-27

5. A triad between sex, necrosis, and inflammation shapes glioblastoma outcomes;Neuro-Oncology;2024-05-14